2024-03-05 21:29:12 ET
Start Time: 16:30
End Time: 17:36
Marinus Pharmaceuticals, Inc. (MRNS)
Q4 2023 Earnings Conference Call
March 05, 2024, 16:30 PM ET
Company Participants
Scott Braunstein - CEO and Chairman
Christy Shafer - Chief Commercial Officer
Joseph Hulihan - Chief Medical Officer
Steven Pfanstiel - CFO and COO
Sonya Weigle - SVP, IR, Human Resources and Corporate Affairs
Conference Call Participants
Brian Abrahams - RBC Capital Markets
Peyton Bohnsack - TD Cowen
Andrew Tsai - Jefferies
Charles Duncan - Cantor Fitzgerald
Joon Lee - Truist Securities
Basma Radwan - Leerink Partners
Douglas Tsao - HC Wainwright
Jason Butler - Citizens JMP
Brian Skorney - Baird
Presentation
Operator
Ladies and gentlemen, greetings and welcome to Marinus Pharmaceuticals' Fourth Quarter and Full Year 2023 Financial Results and Business Update Call. Today's call is being recorded and all lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]. Thank you.
And it is my pleasure to introduce your host, Sonya Weigle, Senior Vice President of Investor Relations, Human Resources and Corporate Affairs. Ms. Weigle, you may begin.
Sonya Weigle
Thank you and good morning. With me from Marinus are Dr. Scott Braunstein, Chairman and Chief Executive Officer; Christy Shafer, Chief Commercial Officer; Dr. Joe Hulihan, Chief Medical Officer; and Steve Pfanstiel, Chief Financial Officer and Chief Operating Officer.
Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including Form 10-K, 10-Q and 8-K.
I will now turn the call over to our CEO, Dr. Scott Braunstein.
Scott Braunstein
Thank you, Sonya. Marinus concluded 2023 with a strong finish across all fronts; commercial, clinical and operational. On today's call, I'll provide a brief overview of some of the key areas before turning it over to our leadership team. ...
Read the full article on Seeking Alpha
For further details see:
Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript